TABLE 1.
Baseline characteristics
| Characteristics and therapeutic strategies | n (%) |
|---|---|
| Ages (years) | |
| Median (range) | 58 (14–84) |
| ≥60 | 62 (45.6) |
| Sex | |
| Male | 115 (84.6) |
| Female | 21 (15.4) |
| ECOG performance status | |
| 0–1 | 78 (57.4) |
| 2 | 58 (42.6) |
| Alcohol use | |
| Current or previous | 54 (39.7) |
| Never | 82 (60.3) |
| Metastasis present | |
| Extrahepatic disease | 101 (74.3) |
| Lung | 52 (38.2) |
| Lymph nodes | 61 (44.9) |
| Bone | 11 (8.1) |
| Peritoneum | 12 (8.8) |
| Intra‐abdominal implantation | 7 (5.1) |
| Adrenal gland | 7 (5.1) |
| Child‐Pugh stage | |
| A | 109 (80.1) |
| B | 27 (19.9) |
| BCLC stage | |
| B | 12 (8.8) |
| C | 124 (91.2) |
| Alpha‐Fetoprotein | |
| <400 (IU/ml) | 73 (53.7) |
| ≥400 (IU/ml) | 63 (46.3) |
| Macrovascular invasion | 68 (50.0) |
| Viral status | |
| Uninfected | 12 (8.8) |
| Hepatitis B | 124 (91.2) |
| Hepatitis C | 0 (0) |
| Liver cirrhosis | 108 (79.4) |
| Prior therapies | |
| Surgery | 67 (49.3) |
| LRT a | 92 (67.6) |
| Immunotherapy | 14 (10.3) |
| Antiangiogenic therapy | 47 (34.6) |
| Previous systemic treatment line | |
| 0 | 80 (58.8) |
| ≥1 | 56 (41.2) |
| With additional LRT a | 63 (46.3) |
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; LRT, locoregional therapy; TACE, transcatheter arterial chemoembolization.
a
LRT includes TACE, ablation, radiation, or seed implantation.